Status:

WITHDRAWN

Natural History of Intestinal Inflammation in People With Primary Immune Dysregulations

Lead Sponsor:

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions:

Chronic Granulomatous Disease

Inflammatory Bowel Disease

Eligibility:

All Genders

3+ years

Brief Summary

Background: PIDD stands for primary immune dysregulation. It is a general term that includes many different inherited immune system disorders. The immune system is the part of the body that helps fig...

Detailed Description

Over 1 million people suffer from IBD in the United States. Although the exact pathogenesis is unclear, IBD results from an inappropriate inflammatory response to intestinal microbes which is influenc...

Eligibility Criteria

Inclusion

  • INCLUSION CRITERIA:
  • General Inclusion Criteria - All individuals must meet the following criteria to be eligible for study participation:
  • Age greater than or equal to 3 years.
  • Willing to allow storage of samples for future research.
  • Willing to allow genetic testing of their samples.
  • Negative urine or serum pregnancy test for women of childbearing potential.
  • Specific Inclusion Criteria for PIDD of Interest Cohort: Enrollment as a patient with confirmed PIDD or carrier status in a current NIH protocol, regardless of an IBD component.
  • Specific Inclusion Criteria for IBD Cohort:
  • Enrollment as a patient with confirmed IBD in a current NIH protocol.
  • Absence of clinical findings or history suggestive of a primary or acquired immunodeficiency (not including immunodeficiency caused by certain IBD treatments).
  • Specific Inclusion Criteria for non-PIDD/non-IBD Cohort (Healthy Volunteers):
  • Absence of clinical findings or history suggestive of a primary or acquired immunodeficiency.
  • Absence of clinical findings or history suggestive of IBD.
  • EXCLUSION CRITERIA:
  • General Exclusion Criteria - An individual who meets any of the following criteria will be excluded from study participation:
  • Active malignancy requiring treatment.
  • HIV.
  • Current treatment for hepatitis B.
  • Current treatment for hepatitis C.
  • Recreational IV drug use within the past 6 months (based on subject report).
  • Participation in a research study of an investigational vaccine within the past 6 months.
  • Any condition that, in the opinion of the investigator, contraindicates participation in this study.
  • Specific Exclusion Criteria for PIDD of Interest Cohort: None.
  • Specific Exclusion Criteria for IBD Cohort: None.
  • Specific Exclusion Criteria for non-PIDD/non-IBD Cohort (Healthy Volunteers):
  • Treatment with systemic antimicrobials within the past 3 months, unless it is a prophylactic regimen consisting of either an azole , trimethoprim-sulfamethoxazole, a quinolone, or any antimicrobial regimen resembling a typical prophylaxis regimen used to treat a PIDD of interest.
  • Treatment with immune modulators within the past 6 months.

Exclusion

    Key Trial Info

    Start Date :

    September 8 2023

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ACTUAL

    End Date :

    September 8 2023

    Estimated Enrollment :

    Patients enrolled

    Trial Details

    Trial ID

    NCT03278912

    Start Date

    September 8 2023

    End Date

    September 8 2023

    Last Update

    September 13 2023

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    National Institutes of Health Clinical Center

    Bethesda, Maryland, United States, 20892